Viridian Therapeutics Inc (VRDN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $22.00 (+0.32%), Market cap $1.78B, 52-week low–high $13.30 ~ $33.78.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comp
Financial statements, price targets, institutional (13F) holdings and related news for Viridian Therapeutics Inc are updated in real time on BlackAll Trade.
Viridian Therapeutics Inc trades at $22.00 (+0.32%). Real-time quotes and charts are available on BlackAll Trade.
Viridian Therapeutics Inc has a market cap of about $1.78B.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including